Evidence map›Paper›PMID 41888394›Full record

ArticleScientific reports2026

Preparation of Co-Ce-Ru/γ-Al

Yuxiu Zhang, Enming Zhang, Jin Deng, Xiaobing Wang

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuxiu ZhangSchool of Chemistry & Civil Engineering, Shaoguan University, Shaoguan, 512005, China. zyx2021@sgu.edu.cn.ORCID http://orcid.org/0000-0001-6703-7658
Enming ZhangSchool of Chemistry & Civil Engineering, Shaoguan University, Shaoguan, 512005, China.
Jin DengSchool of Chemistry & Civil Engineering, Shaoguan University, Shaoguan, 512005, China.
Xiaobing WangSchool of Chemistry & Civil Engineering, Shaoguan University, Shaoguan, 512005, China. sgu_20211005@163.com.

Funding

2022 Shaoguan City Supporting Research Worker Project 220531134531794Natural Science Research Project of Shaoguan University SZ2023KJ05Research Funding for Talent Introduction of Shaoguan University 408-9900064708
6 · The paper itself

Abstract

Dye wastewater is a typical refractory organic wastewater. Advanced oxidation processes have been proven to be an effective way for treating high concentration dye wastewater. This method, which activates peroxymonosulfate (PMS) with cobalt-based catalysts and produces sulfate radicals, has garnered significant research interest. This study developed a highly efficient and environmentally friendly cobalt-based catalysts Co–Ce–Ru/γ-Al2O3 via an impregnation method for enhanced activation of PMS to degrade rhodamine B (RhB) in wastewater. The innovative incorporation of rare-earth metal Ce and precious metal Ru into Co/γ-Al2O3 significantly reduced cobalt loading while improving catalytic activity and stability. The decolorization rate of RhB in dye wastewater was used as the degradation performance index. Results showed that the decolorization rate of RhB using Co–Ce–Ru/γ-Al2O3 catalyst was close to 100% when the system temperature was 25 °C, the amount of catalyst was 0.5 g/L, the amount of PMS was 0.5 g/L, and the concentration of RhB was 50 mg/L. Importantly, the catalyst exhibited exceptional durability with minimal metal leaching (< 1.0 mg/L) over multiple cycles, complying with environmental standards. This work provides deep insights into the catalytic mechanism and kinetics of PMS activation, offering a practical and sustainable solution for the treatment of dye-contaminated wastewater.

Indexed as

Advanced oxidation processesCobalt-based catalystCo–Ce–Ru/γ-Al2O3Dye wastewaterRhodamine B

Identifiers

PMID41888394
PMCPMC13172375

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.